|
Sign In to gain access to subscriptions and/or personal tools.
|
Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis
R Egg
Department of Neurology, University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
M Reindl
Department of Neurology, University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
F Deisenhammer
Department of Neurology, University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
C Linington
Department of Neuroimmunology, Max Planck Institute for Neurobiology, D-82152 Martinsried, Germany
T Berger
Department of Neurology, University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
In a subset of multiple sclerosis (MS) patients antibodies against myelin antigens seem to be important in the demyelinating process. In this study we investigated IgM, IgA and IgG serum antibodies against the myelin oligodendrocyte glycoprotein (MOG) and the myelin basic protein (MBP) in 261 MS patients. Seventy-two per cent had anti-MOG antibodies, 59% were anti-MBP seropositive. The dominating antibody was anti-MOG IgM. A significant relationship between IgA and a progressive disease course was found. The predominance of IgG1 together with the significantly associated occurrence of IgG3 against MOG corresponds to the prevailing IgG1 and IgG3 isotypes in other autoimmune diseases. Patients who actually suffered from a relapse were significant more often anti-MOG and anti-MBP IgG3 seropositive than those in remission. However, patients treated either with intravenous immunoglobulins or interferon-b showed a significant reduction of anti-MOG IgG3 antibodies.
Key Words: immunoglobulin • myelin basic protein • myelin oligodendrocyte glycoprotein • IgG-subclass • IgM • IgA
Multiple Sclerosis, Vol. 7, No. 5,
285-289 (2001)
DOI: 10.1177/135245850100700503
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H Zephir, D Lefranc, S Dubucquoi, J de Seze, L Boron, L Prin, and P Vermersch
Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis
Multiple Sclerosis,
May 1, 2009;
15(5):
593 - 600.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Wang, K. L. Munger, M. Reindl, E. J. O'Reilly, L. I. Levin, T. Berger, and A. Ascherio
Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults
Neurology,
October 7, 2008;
71(15):
1142 - 1146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Tomassini, L. De Giglio, M. Reindl, P. Russo, I. Pestalozza, P. Pantano, T. Berger, and C. Pozzilli
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
Multiple Sclerosis,
November 1, 2007;
13(9):
1086 - 1094.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J.-F. Jegou, P. Chan, M.-T. Schouft, M. R. Griffiths, J. W. Neal, P. Gasque, H. Vaudry, and M. Fontaine
C3d Binding to the Myelin Oligodendrocyte Glycoprotein Results in an Exacerbated Experimental Autoimmune Encephalomyelitis
J. Immunol.,
March 1, 2007;
178(5):
3323 - 3331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Pelayo, M. Tintore, X. Montalban, A. Rovira, C. Espejo, M. Reindl, and T. Berger
Antimyelin Antibodies with No Progression to Multiple Sclerosis
N. Engl. J. Med.,
January 25, 2007;
356(4):
426 - 428.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S J Pittock, M Reindl, S Achenbach, T Berger, W Bruck, F Konig, Y Morales, H Lassmann, S Bryant, S B Moore, et al.
Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations
Multiple Sclerosis,
January 1, 2007;
13(1):
7 - 16.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Urich, I. Gutcher, M. Prinz, and B. Becher
Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors
PNAS,
December 5, 2006;
103(49):
18697 - 18702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. R. Kim, E. Y. Kim, J. Cerny, and K. D. Moudgil
Antibody Responses to Mycobacterial and Self Heat Shock Protein 65 in Autoimmune Arthritis: Epitope Specificity and Implication in Pathogenesis
J. Immunol.,
November 15, 2006;
177(10):
6634 - 6641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E T Lim, T Berger, M Reindl, C M Dalton, K Fernando, G Keir, E J Thompson, D H Miller, and G Giovannoni
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis
Multiple Sclerosis,
August 1, 2005;
11(4):
492 - 494.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Hohlfeld
Immunologic factors in primary progressive multiple sclerosis
Multiple Sclerosis,
June 1, 2004;
10(1_suppl):
S16 - S22.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Hohlfeld
Immunologic factors in primary progressive multiple sclerosis
Multiple Sclerosis,
May 1, 2004;
10(3_suppl):
S16 - S22.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Mantegazza, P. Cristaldini, P. Bernasconi, F. Baggi, R. Pedotti, I. Piccini, N. Mascoli, L. L. Mantia, C. Antozzi, O. Simoncini, et al.
Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association
Int. Immunol.,
April 1, 2004;
16(4):
559 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Berger, P. Rubner, F. Schautzer, R. Egg, H. Ulmer, I. Mayringer, E. Dilitz, F. Deisenhammer, and M. Reindl
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event
N. Engl. J. Med.,
July 10, 2003;
349(2):
139 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Khare, M. Rodriguez, and C. S. David
HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis
Int. Immunol.,
April 1, 2003;
15(4):
535 - 546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
